3 completed, 1 recruiting, 1 terminated, 1 withdrawn. 6 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Respiratory Viral Infection: new trials by email Literature Review of Respiratory Viral Infection trials Research Report on Respiratory Viral Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses AP1189, 100 mg, Placebo - Respiratory Viral Infection | Phase 2 | Recruiting | SynAct Pharma Aps | 96 | 2026-05-01 | 2026-07-28 |
| RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Vapendavir, Placebo - COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection | Phase 2 | Completed | Altesa Biosciences, Inc. | 52 | 2023-11-20 | 2025-09-30 |
| Zinc and Green Tea Extract for Community Respiratory Viral Infections zinc-green tea extract-ascorbic acid, Placebo - Respiratory Viral Infection | Phase 2 | Terminated | University of Missouri-Columbia | 17 | 2022-09-21 | 2025-03-07 |
| An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness Mitoquinone/mitoquinol mesylate - Respiratory Viral Infection, Antiviral Treatment | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 80 | 2022-04-28 | 2025-12-16 |
| PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) RESP301 (a nitric oxide generating solution), Standard of Care (SOC) - Respiratory Viral Infection, Respiratory Tract Diseases | Phase 2 / Phase 3 | Withdrawn | Thirty Respiratory Limited | 2021-09-01 | 2024-01-12 | |
| Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients Cretan IAMA - Covid19, Viral Infection | Phase 2 / Phase 3 | Completed | University of Crete | 20 | 2020-04-01 | 2021-01-12 |
COVID-19 (2) · Respiratory Tract Diseases (2) · Virus Diseases (2) · Common Cold (1) · Communicable Diseases (1) · Emphysema (1) · Enterovirus Infections (1) · Infections (1) · Influenza, Human (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Pulmonary Disease, Chronic Obstructive (1) · RNA Virus Infections (1) · Respiration Disorders (1) · Respiratory Tract Infections (1)
Infections (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Disease Attributes (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Pneumonia (2) · Pneumonia, Viral (2) · Virus Diseases (2) · Chronic Disease (1)
N-(3-(1-(2-nitrophenyl)-1H-pyrrol-2-yl)allylidenamino)guanidine (1) · Standard of Care (1) · mitoquinone (1)
Altesa Biosciences, Inc. (1) · SynAct Pharma Aps (1) · Thirty Respiratory Limited (1) · University of California, Los Angeles (1) · University of Crete (1) · University of Missouri-Columbia (1)
United Kingdom (2) · United States (2) · Bosnia and Herzegovina (1) · Greece (1) · Montenegro (1) · New Zealand (1) · Serbia (1)
Christos Lionis (1) · Onn Min Kon, MD (1) · Onn Min Kon, Professor (1) · Theodoros Kelesidis, MD PHD (1)
PMID 25645191, PMID 28934952, PMID 33390932, PMID 38471990, PMID 9872255